A Novel Dermorphin-Based Painkiller Recruits Endogenous Opioid Peptides for Enhanced Analgesia

A novel dermorphin tetrapeptide analog produced analgesia partly through triggering endogenous opioid peptide release, confirming the drug-endogenous peptide amplification principle for enhanced pain relief.

Mizoguchi, Hirokazu et al.·European journal of pharmacology·2007·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-01268Animal StudyPreliminary Evidence2007RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Amidino-TAPA, a novel dermorphin tetrapeptide analog, produced antinociception partly mediated by endogenous opioid peptide release (confirmed by antiserum blocking), extending the drug-endogenous amplification mechanism to a new opioid drug class.

Key Numbers

How They Did This

animal-study study on opioid-peptides, pain.

Why This Research Matters

Relevant for opioid-peptides, pain, peptide-design.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Amidino-TAPA, a novel dermorphin tetrapeptide analog, produced antinociception partly mediated by endogenous opioid peptide release (confirmed by anti
Evidence Grade:
preliminary evidence.
Study Age:
Published in 2007.
Original Title:
Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.
Published In:
European journal of pharmacology, 560(2-3), 150-9 (2007)
Database ID:
RPEP-01268

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What was studied?

A Novel Dermorphin-Based Painkiller Recruits Endogenous Opioid Peptides for Enhanced Analgesia

What was found?

A novel dermorphin tetrapeptide analog produced analgesia partly through triggering endogenous opioid peptide release, confirming the drug-endogenous peptide amplification principle for enhanced pain relief.

Read More on RethinkPeptides

Cite This Study

RPEP-01268·https://rethinkpeptides.com/research/RPEP-01268

APA

Mizoguchi, Hirokazu; Watanabe, Chizuko; Watanabe, Hiroyuki; Moriyama, Kaori; Sato, Bunsei; Ohwada, Keiko; Yonezawa, Akihiko; Sakurada, Tsukasa; Sakurada, Shinobu. (2007). Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.. European journal of pharmacology, 560(2-3), 150-9.

MLA

Mizoguchi, Hirokazu, et al. "Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.." European journal of pharmacology, 2007.

RethinkPeptides

RethinkPeptides Research Database. "Involvement of endogenous opioid peptides in the antinocicep..." RPEP-01268. Retrieved from https://rethinkpeptides.com/research/mizoguchi-2007-involvement-of-endogenous-opioid

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.